Effect of Orlistat and Sibutramine Cessation on Obesity Indices and Cardiovascular Risk Factors in Obese Subjects.
Objective: The effects of ceasing anti-obesity drugs on anthropometric profile and cardiovascular risk have not been well studied. We aimed to evaluate the effects of orlistat and sibutramine cessation after a 9 months weight loss programme on anthropometric profile and cardiovascular risk factors....
| Publicado en: | International Medical Journal Vol. 22; no. 4; pp. 232 - 238 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Japan International Cultural Exchange Foundation
Aug2015
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109212352&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 109212352 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 13412051 23J1 jtl: International Medical Journal issn: 13412051 maglogo: N pubinfo: dt: Aug2015 vid: 22 iid: 4 pid: 29386 pub: Japan International Cultural Exchange Foundation artinfo: ui: 109212352 109212352 109212352 109212352 ppf: 232 ppct: 6 formats: fmt: @attributes: type: P tig: atl: Effect of Orlistat and Sibutramine Cessation on Obesity Indices and Cardiovascular Risk Factors in Obese Subjects. aug: au: Samp, Zulkefli Al-Tahami, Belqes Abdullah Mohammad Ariffin, Farah Diana Omar, Noor Salwah S. Rasool, Aida Hanum Ghulam affil: Central Research Laboratory, School of Medical Sciences, Universiti Sains Malaysia Kota Bharu, Malaysia sug: subj: Orlistat Sibutramine Obesity Drug Therapy Cardiovascular Risk Factors Substance Withdrawal, Controlled Human Anthropometry Weight Loss Orlistat Administration and Dosage Sibutramine Administration and Dosage Blood Pressure Evaluation Blood Glucose Analysis Insulin Blood Energy Metabolism Body Weight Body Mass Index Waist Circumference Adipose Tissue Triglycerides Blood Weight Gain Prospective Studies ab: Objective: The effects of ceasing anti-obesity drugs on anthropometric profile and cardiovascular risk have not been well studied. We aimed to evaluate the effects of orlistat and sibutramine cessation after a 9 months weight loss programme on anthropometric profile and cardiovascular risk factors. Methods: 36 obese subjects who had undergone a 9 months weight loss programme with orlistat and sibutramine were followed up 4 months after ceasing the anti-obesity drugs. 18 subjects received 120 mg orlistat three times daily and 18 were on 10-15 mg sibutramine daily. Anthropometric and metabolic profiles, fasting blood sugar, insulin levels, insulin resistance (HOMA-IR), blood pressure, systemic arterial stiffness (quantified as central augmentation index) and energy expenditure were measured during 9 months treatment and 4 months after ceasing anti-obesity drugs. Results: After cessation, there were significant increases in body weight (80.25 vs 77.40 kg), BMI (32.76 vs 31.56 kg/nf), waist circumference (93.03 vs 91.44 cm), body fat percentage (38.36 vs 37.52%), visceral fat percentage (15.39 vs 13.85%), triglyceride levels (1.32 vs 1.13 mmol/l), fasting blood sugar (4.76 vs 4.51 mmol/1) and systemic arterial stiffness (21.93 vs 19.77%). The magnitude of weight regain was smaller to that lost during orlistat treatment, but was higher in sibutramine-treated group. Conclusion: Orlistat and sibutramine cessation produced weight regain and increased certain obesity indices as early as 4 months after cessation. Continuous rigorous follow up and reinforcement is needed to ensure weight regain is prevented or minimized to maintain beneficial effects achieved with anti-obesity drug treatment. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|